REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory CompositionsRadionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/09/07 - 20070183969 - Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone ... 08/02/07 - 20070178044 - Methods for detecting dna damage and screening for cancer therapeutics A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is ... 07/26/07 - 20070172422 - Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications The present invention relates to the compositions, methods, and applications of a new approach to pattern recognition based targeting by which an exponential amplification of effector response can be specifically obtained at a targeted cells. The purpose of this invention is to enable the selective delivery of large quantities of ... 07/26/07 - 20070172421 - Substituted pyrrolidine-2-ones Wherein R1, R2, R3, R4 and n are as defined in the specification, to processes for their manufacture, to their use as pharmaceuticals, in diagnosis, as PET ligands and to pharmaceutical or diagnostic compositions comprising such compounds. ... 07/26/07 - 20070172420 - Ligands and pharmaceutically-acceptable salts thereof, wherein R1 and Ar are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare ... 07/19/07 - 20070166229 - Cardiovascular safety assay The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during ... 07/19/07 - 20070166228 - Neutral labeling reactants and conjugates derived thereof This invention concerns novel neutral labeling reactants. The novel reactants are derivatives of diethylenetriaminepentaacetic acid (DTPA) diamides, wherein a suitable group is linked to the molecule allowing introduction of the chelating agent or the neutral chelate to bioactive molecules. ... 07/19/07 - 20070166227 - Crowned dithiocarbamate metal complexes and methods for their use Compositions containing crowned dithiocarbamate metal complexes and methods of using these compositions; neutral and cationic radioactive metal-nitrido complexes of crowned dithiocarbamates (DTCs) and methods of using these complexes as radiopharmaceuticals for diagnosis and treatment of cardiovascular disorders, infectious diseases, and cancer; tripodal chelatormetal complexes of crowned DTCs and methods of ... 07/12/07 - 20070160527 - Use of n-acetyl-d-aminoglycosamine in treatment of local lesions or systematic symptoms related to autoimmune reactions The present invention discloses a method for treating local lesions or systematic symptoms caused by autoimmune reactions, a use of N-acetyl-D-glucosamine for treating local lesions or systematic symptoms caused by autoimmune reactions, and a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating local lesions or systematic symptoms ... 07/12/07 - 20070160526 - Detection, monitoring and treatment of cancer and compounds comprising these aptamers and sequences. There are also disclosed compounds having the structure formula (I) and (II). There are also disclosed methods of treatment, diagnosis, detection and imaging using these compounds, their use in such methods, and their use in the preparation of medicaments and products for such ... // - 22 - ... // - 21 - ... // - 20 - ... // - 19 - ... // - 18 - ... // - 17 - ... // - 16 - ... // - 15 - ... // - 14 - ... // - 13 - ... // - 12 - ... // - 11 - ... // - 10 - ... 07/05/07 - 20070154391 - Antibodies to vascular endothelial cell growth factor The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either ... 06/28/07 - 20070148088 - Cytotoxic therapy Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of ... 06/28/07 - 20070148087 - Tame based chelators and uses thereof New bifunctional chelation complexes are described. These are based on the structure of the so-called “TAME-HexA” molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes. ... 06/21/07 - 20070140962 - Light sensitive compounds for instant determination of organ function Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume ... 06/21/07 - 20070140961 - Radiotherapeutic high specific activity tin-117m and methods of use The present invention provides a radiotherapeutic composition comprising a high specific activity tin-117m source of radiotherapeutic atomic electrons and a delivery vehicle, e.g., a chelator or nanosphere or microsphere effective to contain tin-117m therein. The present invention also provides a targeting moiety linked to the delivery vehicle. Further provided are ... 06/21/07 - 20070140960 - Methods for imaging soluble a-beta Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue. ... 06/21/07 - 20070140958 - Rubidium generator for cardiac perfusion imaging and method of making and maintaining same An 82Sr/82Rb generator column is made using a fluid impervious cylindrical container having a cover for closing the container in a fluid tight seal, and further having an inlet for connection of a conduit for delivering a fluid into the container and an outlet for connection of a conduit for ... 06/21/07 - 20070140957 - Hierarchical chromonic structures A method of making a chromonic structure comprises (a) preparing a first aqueous mixture comprising (i) a continuous water-soluble polymer phase and (ii) a discontinuous chromonic phase comprising a chromonic material, to form chromonic nanoparticles; (b) non-covalently crosslinking the resulting chromonic nanoparticles with a multivalent cation salt; (c) dispersing the ... 06/07/07 - 20070128110 - Stereoisomers of fatty acid analogs for diagnostic imaging The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more ... 06/07/07 - 20070128109 - Stabilized and lyophilized radiopharmaceutical agents for destroying tumors A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal ... 06/07/07 - 20070128108 - Therapy of malignant neoplasias The present invention provides a method for the treatment of malignant neoplasias comprising the step of administering an L-phenylalanine conjugated to a beta- or alpha-emitting isotope to a subject in the need thereof. Moreover, the invention provides a method for the monitoring of the progress of such treatment of malignant ... 06/07/07 - 20070128107 - Method to detect dopamine receptors in the functional d2high state This application describes a method for identifying dopamine supersensitivity using radioactive (+)PHNO. The method involves determining the specific binding of radioactive (+)PHNO is the subject's brain. An increase in the specific binding of radioactive (+)PHNO in the subject compared to a control indicates that the subject is in a state ... 05/31/07 - 20070122342 - Ethylenedicysteine (ec)-drug conjugates compositions and methods for tissue specific disease imaging The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a ... 05/31/07 - 20070122341 - Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques wherein R1-R5 are independently selected from hydrogen, C1-C4 alkyl and F (at least one of them is F) and each R6-R10 are independently selected from hydrogen, C1-C4 alkyl, OH, OCH3, NH2, NHCH3 and N(CH3)2 (at least one of them is OH, OCH3, NH2, NHCH3 or N(CH3)2) are disclosed. Benzylideneaniline derivatives ... 05/31/07 - 20070122340 - Necrosis avid tracer agent The present invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. ... 05/17/07 - 20070110667 - Radionuclide labeling of vitamin b12 and coenzymes thereof is derived from a corrin carboxylic acid group of said cobalamin, Y is a linking group and X is a chelating group, optionally comprising a detectable radionuclide or a paramagnetic metal ion, and n is 1-3. ... 05/17/07 - 20070110666 - Methods for preparation of live body tissues for examination A minimally invasive procedure for perfusion-impregnation of tissues, organs and cells is provided that aids in the retention of tissue and cellular architecture without the formation of artifacts. The procedure allows for monitoring drug disposition, for detecting diseased tissue and for monitoring the presence of target molecules in a sample ... 05/17/07 - 20070110665 - Tissue marker for multimodality radiographic imaging An implantable tissue marker incorporates a contrast agent sealed within a chamber in a container formed from a solid material. The contrast agent is selected to produce a change, such as an increase, in signal intensity under magnetic resonance imaging (MRI). An additional contrast agent may also be sealed within ... 05/17/07 - 20070110664 - Method and apparatus for synthesis of [11c] phosgen using concentrated [11c] carbon monoxide with uv light Methods and systems for labeling synthesis of phosgen by UV light are provided. Methods of synthesizing labeled compounds useful as PET tracers from labeled phosgen are also provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography. Associated kits for PET studies are ... 05/10/07 - 20070104646 - Stabilized and lyophilized radiopharmaceutical agents A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal ... 05/10/07 - 20070104645 - Chelate based scaffolds in tumor targeting This invention relates to novel complexes that can be used to target tumor cells. The complexes include a ligand that can bind metal ions including radioactive lanthanide ions. The complexes can mimic ανβ3 integrin receptor antagonists and deliver the complexed radioactive metals to the tumor cells. ... 05/10/07 - 20070104644 - Inhibitor imaging agents The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the sulphonamide hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body. ... 05/03/07 - 20070098632 - Analogs of terpene trilactones from ginkgo biloba and related compounds and uses thereof wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R2 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; R3 is H or OH; R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and wherein ... 05/03/07 - 20070098631 - Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic namely Biphenyl; Arylpiperidine; Arylpiperazine; 1,4 dyhydropyridine; Dihydropyrimidone; 1,4 benzodiazepine-2-one; 1,5 benzodiazepine-2-one; 1,4-benzodiazepine-2,5 diones; pyrrolo2,1-c 1,4 benzodiazepines 5,11 diones; 1,4 benzothiazepine-5-ones; 5,11-dihydro-benzo pyrido 3,2b 1,4 diazepine-6-ones Benzopyrane; Chromone; Benzopyranone; Coumarine, pyranocoumarine Benzopiperazinones; Quinazolinone; Quinazolindione; Quinoxalinone Imidazoquinoxaline; indole; Benzimidazole Benzofurane Benzothiophene; SIGNAL is a signal entity for medical imaging diagnostic, and pharmaceutically ... 04/26/07 - 20070092442 - F-18-fluorinated phosphonium cation imaging agents and methods of synthesis The present disclosure provides mitochondrial imaging probes, particularly imaging probes capable of imaging changes in mitochondrial membrane potential and conditions associated with mitochondrial dysfunction. ... 04/26/07 - 20070092441 - Fluoridation method A method for the fluoridation of an iodonium salt with a fluoride ion source which can be carried out in an aqueous reaction solvent. ... 04/26/07 - 20070092440 - Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial The present invention relates to a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that ... 04/12/07 - 20070081941 - F-18 labeled amino acid analogs R is (C1-C6)alkyl optionally substituted with thioether or ether oxygen atom when n=0, or a substituted aromatic or heteraromatic ring when n=1-6; and m=0 or 1; and X is a halogen atom. The invention further relates to precursor compounds for these analogues, to a method of preparing these analogues, to ... 04/12/07 - 20070081940 - Radioactive source materials formable into various shapes The present invention provides an integral source material, the integral source material has at least one nuclide that is an integral source material having at least one nuclide that is activatable by exposure to radiation, the nuclide is a chemically bound constituent of a polymer of the integral source material, ... 04/05/07 - 20070077198 - Method for preparing radiolabeled thymidine having low chromophoric byproducts The invention is a method and related precursor for preparing 18F-FLT. The precursor has a butoxycarbonyl protecting group at the 5′-position that results in low amounts of chromophoric byproducts being formed during deprotection. The method for preparing 18F-FLT is efficient and makes the final purification step less complicated. ... 04/05/07 - 20070077197 - Metal complexes derivatized with folate for use in diagnostic and therapeutic applications Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the α, γ, or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a ... 04/05/07 - 20070077196 - Radiolabeled thymidine solid-phase extraction purification method A method and an apparatus for the manufacture of 3′-deoxy-3′-[18F]Fluorothymidine are disclosed. A fluorothymidine precursor, a reaction solvent for the fluorothymidine precursor, a source of [18F] ions, and dilution water are combined to form a reaction mixture including a radiolabeled thymidine product, [18F] ions, and residual reaction impurities. The reaction ... 04/05/07 - 20070077195 - n and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3 (co)3]+ by fac coordination The present invention relates to novel histidine derivatives that can be used for the labeling of biomolecules with radioactive metal tricarbonyls. The new derivatives have a histidine that is derivatized at the Nε and at least protected at the Nα and optionally at the Nδ; or derivatized at the Nα ... 03/29/07 - 20070071673 - Trifunctional reagent for conjugation to a biomolecule A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with ... 03/29/07 - 20070071672 - Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents The invention relates to the use of metal tricarbonyl compounds of the general formula [M(CO),L,]′, wherein M is rhenium or technetium or an isotope thereof and L is a ligand, for the preparation of a medicament for the treatment of cancer that is both radiotherapeutic and chemotoxic when a radioactive ... 03/29/07 - 20070071671 - Process for producing radioactive-fluorine-labeled compound An on-column process by which various radioactive-fluorine-labeled compounds can be obtained in a high yield. The process comprises a step in which [18O] water containing [18F] fluoride ions is introduced into a column packed with an anion-exchange resin for labeled-compound synthesis to collect the [18F] fluoride ions, a step in ... 03/29/07 - 20070071670 - Diagnostic imaging agents with mmp inhibitory activity The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the ... 03/22/07 - 20070065360 - Nonpolar thymidine analogs X1 and X2 are independently selected from I, Cl, Br, and F, with the proviso that not more than one F will be present at these positions. ... 03/22/07 - 20070065359 - Nanocells for diagnosis and treatment of diseases and disorders The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells ... 03/15/07 - 20070059239 - Process for the preparation of radioactive labeled estradiol A method for producing a high yield of an estradiol labeled at the 16-alpha position thereof with a radioactive iodine, especially 123I, for use as an imaging agent. The method includes the step of mixing a source of 123I sodium iodine with 16-beta-bromoestradiol-17-beta and benzo-15-crown-5-ether in a water and organic ... 03/08/07 - 20070053834 - Radioligands for the trp-m8 receptor and methods therewith One embodiment of the invention is a composition that comprises a radioactive [18F], [76Br]-, [77Br]-, [211At]-, [123I], [125I], or [131I]-N-radioistope-labeled-aryl-alkyl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer ... 03/08/07 - 20070053833 - High dose radionuclide complexes for bone marrow suppression The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such ... 03/08/07 - 20070053832 - Drug product and process for making The invention provides a drug product for treating radiation exposure comprising, a drug in a dosage form; and packaging for the drug together with a package insert or label that includes information about the drug's efficacy, where the information about the drug's efficacy is obtained at least in part from ... 03/08/07 - 20070053831 - Methods for binding agents to b-amyloid plaques A method for labeling structures, such as β-amyloid plaques and neurofibrillary tangles, in vivo or in vitro, is provided and comprises contacting brain tissue with one or more compounds, preferably radiolabeled for detection by positron emission tomography (PET). ... 03/08/07 - 20070053830 - Particulate materials and compositions for radio therapy Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of ... 03/01/07 - 20070048216 - Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is ... 03/01/07 - 20070048215 - Chemical compound and assay The present invention relates to a labelled ligand compound that is useful in a method of identifying, testing and/or screening of compounds modulating ion channels, in particular myocardial I?Kr# 191 channels such as those encoded by ERG, including hERG. The ligand compound is therefore of use to evaluate the affinity ... 02/22/07 - 20070041900 - Method and device for radiotherapy A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the ... 02/22/07 - 20070041899 - Radiolabelled substrates The present invention relates to radiolabelled P-glycoprotein (P-gp) substrates, which are useful for the labeling and diagnostic imaging of P-gp functionality. ... 02/15/07 - 20070036718 - Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives Halogenated carboxylic ester derivatives of phenylethyl imidazole, and their method of preparation are disclosed. Radio-halogenated forms of these compounds are ideally suited for positron-imaging of the adrenal glands, as it is known that these compounds demonstrate a selective and high rate of accumulation in the adrenals. The method of preparing ... 02/15/07 - 20070036717 - Chemoradiotherapy with ts-1/camptothecins An antitumor agent for chemoradiotherapy of rectal cancer comprising a combination of TS-1 (a combination drug of tegafur, gimeracil, and oteracil potassium at a 1:0.4:1 molar ratio) and CPT-11 (irinotecan hydrochloride). The antitumor agent of the invention can achieve marked tumor volume reduction without causing major side effects, especially by ... 02/15/07 - 20070036716 - Methods of making radiolabeled tracers and precursors thereof The present disclosure relates to a solid-phase process for the production of radiolabeled tracers, in particular for the production of 18F-labeled compounds which may be used as Positron Emission Tomography (PET) radiolabeled tracers. The disclosure also relates to radiopharmaceutical kits comprising precursors to the radiolabeled tracers, which can be converted ... 02/15/07 - 20070036715 - Tc-labeled arylpiperazine derivatives for imaging serotonin receptor New arylpiperazine derivatives according to the present invention have no problem of amide hydrolysis in metabolism and have a high affinity for serotonin receptors, and can be labeled with an optimum radionuclide of technetium, thereby being usefully applied for monitoring neurodegenerative diseases or neurological diseases of a mammal. ... 02/15/07 - 20070036714 - Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy The invention concerns compounds of general formula (I), wherein: when A forms a chain with C, called A-C chain, of formula (1): —X—Y—C6H4-(CH2)n1-C(Z,W)—(CH2)n2-C6H4-Y—X—, then B forms a chain with D, the chain of above formula (1), called A-C and B-D chains located independently of each other, above (position alpha ) ... 02/08/07 - 20070031328 - Radiolabeled-pegylation of ligands for use as imaging agents The present invention is directed to a method of using radiolabeled ethylene glycol (n=1) (EG) or polyethylene glycol (n=from 2 to 10) (PEG) as a labeling group moiety on compounds that can be useful for imaging tissues. Specifically, the EG or PEG moiety preferably contains a radiofluorine (18F), and is ... 02/08/07 - 20070031327 - Nanoradiopharmaceuticals and methods of use The present invention is directed to novel compositions and the use thereof More particularly, the present invention relates to nanoradiophannaceuticals, radioactive nanoparticles, and methods of using them for a range of applications including diagnostic imaging and the treatment of disease. ... 02/08/07 - 20070031326 - Compounds that selectively bind to membranes of apoptotic cells This invention provides new small-molecules capable of selective binding to membranes comprising and exposing phosphatidylserine on their surface and/or membranes which have increased amounts of phosphatidylethanolamine in their outer leaflet. ... 02/01/07 - 20070025910 - Anticancer therapy A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions. ... 01/25/07 - 20070020178 - Phospholipid ether analogs as cancer treatment agents and methods thereof The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, ... 01/25/07 - 20070020177 - Radiometal complex compositions The present invention relates to stabilised technetium and rhenium metal complex compositions comprising a radioprotectant and a radiometal complex of a tropane-tetradentate chelating agent conjugate, wherein the radiometal complex is neutral. Radiopharmaceuticals comprising the stabilised metal complex compositions, and kits for the preparation of the radiopharmaceuticals are also described. ... 01/25/07 - 20070020176 - Contrast agent The present invention relates to a contrast agent of Formula I V-L-Z Formula I where V is a non-peptidic vector having affinity for the Angiotensin II receptor, L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an in vivo imaging procedure of ... 01/18/07 - 20070014723 - Methods and compositions for 10beryllium complex probes The present invention concerns methods and compositions for making and using Be complexes of defined compositions, which may have multiple functionalities and/or binding specificities. In various embodiment, Beryllium (Be) complexes may include Be such as 10Be and 7Be complexes. Such complexes find use in a wide variety of applications, particularly ... 01/18/07 - 20070014722 - Method of treating human volume expansion mediated hypertension employing resibufogenin A method of treating volume expansion mediated hypertension including administering a therapeutically effective dose of resibufogenin to a patient having volume expansion mediated hypertension. A method for the determination of the presence of volume expansion mediated hypertension may be by determining whether there has been a substantial elevation in marinobufogenin ... 01/18/07 - 20070014721 - Hydrazide conjugates as imaging agents The present disclosure is directed to diagnostic agents. More specifically, the disclosure is directed to compounds, diagnostic agents, compositions, and kits for detecting and/or imaging and/or monitoring a pathological disorder associated with coronary plaque, carotid plaque, aortic plaque, plaque of the arterial vessel, aneurism, vasculitis, and other diseases of the ... 01/18/07 - 20070014720 - Antibodies directed to cd20 and uses thereof Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning ... 01/18/07 - 20070014719 - Steroid analogs and characterization and treatment methods The invention relates to methods to characterize exemplified compounds such as 3β, 17β-dihydroxyandrost-1,5,11 -triene and 3β, 17β-dihydroxy-17α-ethynylandrost-1,5,11-triene and to the use of described compounds to ameliorate or treat a condition such as thrombocytopenia, inflammation or other exemplified conditions. ... 01/18/07 - 20070014718 - Kits for gastric emptying measurement The present invention provides a test meal kits that are used in the diagnosis of gastrointestinal disorders characterized by changes in the rate of gastric emptying; and, with a breath test or a nuclear scintigraphy scan, are used to measure a half-gastric emptying time useful for therapy monitoring of gastrointestinal ... 01/11/07 - 20070009432 - Boat tropanes Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. ... 01/11/07 - 20070009431 - Solution and method for supporting imaging on a patient To support imaging on a patient, two different image recording methods are to be executed simultaneously. With each image recording method, a supporting fluid, for instance a contrast means or a tracer, can be introduced into the body of the patient. The invention proposes mixing the two supporting fluids with ... 01/11/07 - 20070009430 - Process for the production of a radioactive aerosol A method for forming an inhalable isotope compound suitable for use in patient medical diagnosis, the method comprising the steps of: (a) electrolytic loading of a carbon crucible with the isotope; (b) sublimating any isotope carrier in the crucible; (c) ablating the isotope in a carbon crucible, forming an ablation ... 01/11/07 - 20070009429 - Radiation resistant silicone formulations and medical devices formed of same The disclosure is directed to a polymeric material formed of a composition including polyalkylsiloxane and a radiation resistant component. The radiation resistant component is included in an amount of about 0.1 wt % to about 20 wt % based on the weight of the polyalkylsiloxane. ... 01/11/07 - 20070009428 - Compounds and methods for enhanced delivery to disease targets A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target ... 01/11/07 - 20070009427 - Compounds and methods for enhanced delivery to disease targets A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target ... 01/04/07 - 20070003479 - Diagnostic imaging contrast agents with extended blood retention The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical ... 12/28/06 - 20060292073 - Stereoselective synthesis of amino acid analogs for tumor imaging The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy ... 12/28/06 - 20060292072 - Agents for neutron capture therapy Compounds, pharmaceutical formulations and methods for use in neutron capture therapy are provided, useful for treating diseases characterized by neoplastic tissue and arteriosclerosis. ... 12/07/06 - 20060275209 - Methods of [11c]-radiolabelling phenothiazine and phenothiazine-like compounds This invention pertains to methods of [11C]-radiolabelling “phenothiazine” and “phenothiazine-like” compounds, which have a pendant group (which is a primary amino group; a cationic primary imino group; a secondary amino group; a cationic secondary imino group; a primary imino group; or a secondary imino group), by reaction with [11C]methyl trifluoromethanesulfonate ... 12/07/06 - 20060275208 - Miniaturized 62zn/62cu generator for high concentration clinical delivery of 62cu kit formulation for the facile preparation of radiolabeled cu-bis(thiosemicarbazone)compounds A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of 62Cu-labeled radiopharmaceuticals (62Cu-ligand) can be interchangeably synthesized ... 11/30/06 - 20060269478 - Use of protein occlusion for the selective delivery of small molecules to targets The present invention relates to complexes between (1) a target-binding moiety; (2) a cavity-forming moiety; and (3) a pharmacological compound to be delivered to a target, wherein the pharmacological compound is buried inside of the cavity-forming moiety, but not covalently bound to either the target-binding moiety or the cavity-forming moiety. ... 11/30/06 - 20060269477 - St receptor binding compounds and methods of using the same Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive ... 11/30/06 - 20060269476 - Method for integrating large scale biological data with imaging There is disclosed a method of extracting large scale biological, biochemical or molecular information about an index disease, biological state, or systems from imaging by correlating the imaging features associated with said disease, state or system with corresponding large scale biological data. ... 11/30/06 - 20060269475 - Multi-layer structure having a predetermined layer pattern including an agent Improved controlled therapy is provided with a polymer multi-layer structure having a predetermined micro-fabricated spatial pattern (e.g., reservoirs and channels). More specifically, all geometrical details of the spatial pattern are substantially predetermined. The increased control of pattern geometry provided by the invention allows for improved control of therapy. In preferred ... 11/30/06 - 20060269474 - Stilbene derivatives and their use for binding and imaging amyloid plaques This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method ... 11/30/06 - 20060269473 - Stilbene derivatives and their use for binding and imaging amyoid plaques This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method ... 11/16/06 - 20060257316 - Methods for diagnosing and monitoring treatment adhd by assessing the dopamine transporter level A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment ... 11/16/06 - 20060257315 - Activation and production of radiolabeled particles A method for activating particles for internal radiopharmaceutical use, said particles comprising precursor nuclides to be activated, is disclosed. The method comprises: directing a high-intensity laser beam onto converting means to produce an irradiating field; and irradiating said particles comprising precursor nuclides in said irradiating field to activate said precursor ... 11/09/06 - 20060251578 - Therapeutic and diagnostic compounds, compositions, and methods wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; b) a radionuclide; and c) a radioprotectant. ... 11/09/06 - 20060251577 - Composition and method for direct visualization of the human appendix A positive contrast agent composition containing meglumine diatrizoate, sodium diatrizoate, simethicone, famotidine and aspartame in predetermined amounts that is orally administered to a patient for clinical evaluations of appendicitis wherein a positive contrast effect is achieved. Methods of use include orally administering individual doses of the composition approximately 50 minutes ... 11/09/06 - 20060251576 - Methods for measuring cholesterol metabolism and transport The present invention relates to biochemical methods for determining reverse cholesterol transport (RCT). Specifically, the three components of RCT (efflux, plasma, and excretion) are measured in vivo by administering an isotope-labeled cholesterol or cholesterol-related molecule or cholesterol-related complex, and then measuring the dilution or appearance of isotopes in the various ... 11/09/06 - 20060251575 - Method for preventing nasolacrimal duct obstruction The invention is directed to a method for preventing nasolacrimal duct obstruction (NLDO) in a patient receiving high dose radioactive iodine for treatment of cancer which comprises administering to the eyes of said patient an effective amount of perchlorate anion. ... 11/09/06 - 20060251574 - Cytotoxins and diagnostic imaging agents comprising hsp90 ligands Cytotoxic compounds and diagnostic imaging agents comprising HSP90-ligands and methods of use thereof are described. ... 10/26/06 - 20060239907 - Stealthy nano agents Stealthy nanoagents are provided comprising inorganic shells containing pluralities of nanoagents. The nanoagents are isolated from the environment of the shells. Thereapeutics, imaging and diagnostic methods are also provided. ... 10/12/06 - 20060228298 - Imaging and selective retention of phospholipid ether analogs The present invention generally relates to imaging and selective retention of phospholipid ether analogs in various neoplastic tissues. Specifically, the present invention relates to imaging and methods for selective retention of analogs, for example, NM404, in cancers such as Colorectal Cancer. ... 10/12/06 - 20060228297 - Thorium-227 for use in radiotherapy of soft tissue disease The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such ... 10/12/06 - 20060228296 - Method of screening groups of radioactive molecules and applications thereof The invention relates to an amplification-free method of screening groups of radioactive molecules, the products from the molecule groups obtained and the application thereof in order to identify molecules that are capable of binding selectively to a tissue or a particular organ. The inventive method can be used for the ... 10/05/06 - 20060222587 - Hybrid inorganic nanoparticles, methods of using and methods of making The invention provides hybrid inorganic nanoparticles, methods of making the hybrid inorganic nanoparticles and methods of using the hybrid inorganic nanoparticles. ... 09/28/06 - 20060216230 - Radioactive bone cement for treatment of tumors in bone Conventional internal radiation therapy has used implants, such as granules or seeds, each of which includes a radiation source for implantation within the patient. In contrast to conventional internal radiation therapy, disclosed herein is a radioactive flowable cement capable of curing to form radioactive cured cement, such that the radioactive ... 09/07/06 - 20060198783 - Porphyrin-based compounds for tumor imaging and photodynamic therapy This invention describes a first report on the synthesis of certain 124I-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy ... 08/31/06 - 20060193769 - Drug releasing biodegradable fiber for delivery of therapeutics The present invention relates to fiber compositions comprising gels or hydrogels. The invention further relates to the composition of a gel or hydrogel loaded biodegradable fiber and methods of fabricating such fibers. The present invention further provides tissue engineering and drug-delivery compositions and methods wherein three-dimensional matrices for growing cells ... 08/31/06 - 20060193768 - Contrast agent A contrast agent of formula I: V-L-R (I) where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linear or branched amino acid-comprising biomodifier or linker moiety, and R is a reporter moiety detectable in in vivo imaging of a human or ... 08/24/06 - 20060188438 - Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a ... 08/24/06 - 20060188437 - Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery The present invention provides a tumor-homing peptide that can target cancer and or tumor tissues. The peptide is uptaken by certain specific cancer cell types. The invention describes methods to achieve targeted delivery of anticancer drugs conjugated to this peptide for anticancer therapy. The invention also describes methods for using ... 08/10/06 - 20060177374 - Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments The present invention relates to a method for treating cancer in an animal by administering to the animal an active vitamin D compound or a mimic thereof in combination with a radiotherapeutic agent or treatment. ... 08/10/06 - 20060177373 - Low density radionuclide-containing particulate material The invention relates to a particulate material consisting of a low density radiation-tolerant glass and a radionuclide incorporated into the low density glass or coated on the low density glass, the glass having a density of less than 2.5 g/cm.sup.3, processes for its production and a method of radiation therapy ... 08/03/06 - 20060171882 - Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled compounds by thermally induced free radical carbonylation Methods and reagents for thermally initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with nucleophiles are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided. ... 08/03/06 - 20060171881 - Compounds with high monoamine transporter affinity Featured compounds have high monoamine transport affinity and are characterized by one of the following two general formulas set out above. The compounds bind selectively or non-selectively to monoamine transporters. The compounds are useful to treat various medical indications including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking ... 07/27/06 - 20060165591 - Metal complex-containing pharmaceutical agents Improved metal complex-containing pharmaceutical agents are described which, as an additive, contain one or more complexing agents and/or one or more weak metal complex(es) or mixtures thereof. ... 07/27/06 - 20060165590 - Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters by photo-induced free radical carbonylation Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with alcohols pretreated by a base are provided. The resultant carbon-isotope labeled esters are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided. ... 07/20/06 - 20060159618 - Preparation of compounds useful for the detection of hypoxia Novel 18F-fluorine compounds useful for non-invasive imaging techniques such as PET, for detecting tissue hypoxia and methods for preparing them are disclosed. Novel intermediate compounds and methods for preparing them are also disclosed. Diagnostic kits useful in practicing the methods of claimed invention are also provided. ... 07/20/06 - 20060159617 - Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates the methods of imaging tissues, organs or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which ... 07/20/06 - 20060159616 - Methods for detecting endocrine cancer Kallikrein 13 constitutes a novel biomarker for diagnosis, treatment and monitoring of endocrine cancer. A method is provided for diagnosing and monitoring endocrine cancer or a predisposition to endocrine cancer, in a subject comprising detecting hK13 in a sample from the subject. Imaging methods, screening methods for test agents for ... 07/06/06 - 20060147371 - Water-soluble compound A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least ... 06/29/06 - 20060140856 - Skeletal-targeted radiation to treat bone-associated pathologies The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such ... 06/15/06 - 20060127309 - Imaging agents The present invention provides novel compounds that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging). The present invention also provides imaging compositions for use within nuclear medicine applications. Additionally, the present invention provides methods of imaging. ... 06/15/06 - 20060127308 - Method to improve the efficacy of therapeutic radiolabeled drugs Disclosed are radiolabeled drugs and methods to improve their efficacy by using a radiosensitizer such that the radiosensitizer is either part of the radiolabeled drug by directly attaching the radiosensitizer to the radiolabeled drug or by producing a mixture of the radiolabeled drug and an analogue of the drug with ... 06/15/06 - 20060127307 - Devices and compositions containing boron and silicon for use in neutron capture therapy The present invention relates to a boron containing therapeutic composition comprising: (i) a boron component formed at least partly from boron-10; and (ii) a silicon component. The composition is of value in the treatment of cancers by boron neutron capture therapy or in the treatment of arthritis by boron neutron ... 06/15/06 - 20060127306 - Radioactively labelled amino acid analogues, their preparation and use The present invention relates to Halogenated amino acid analogues for use in diagnosis, which compounds have the genera formula (I) wherein: R is (C1-C6) alkyl optionally substituted with thioether or ether oxygen atom when n=0, or a substituted aromatic or heteraromatic ring when n=1-6; and m=0 or 1; and X ... 06/08/06 - 20060120958 - Solid-phase fluorination of uracil and cytosine The invention relates to a process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LINKER-I+-TRACER (I) Y− wherein the TRACER is of formula (A): or an amine protected derivative thereof, wherein Y− is an anion, preferably trifluoromethylsulphonate (triflate) anion; ... 06/08/06 - 20060120957 - Radioactive transition metal-imido hetero-diphosphine complexes, their preparation and radiopharmaceutical compositions thereof The present invention provides radioactive metal heterocomplexes of formula (I): [(Me═N—R)L1L2]+Z. (I), wherein Me, R, L1 L2 and Z− have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ... 06/08/06 - 20060120956 - Imaging agents comprising barbituric acid derivatives The present invention relates to diagnostic imaging agents for in vivo imaging. The imaging agents comprise a synthetic barbituric acid derivative labelled at the 5-position with an imaging moiety suitable for diagnostic imaging in vivo. The invention also provides pharmaceutical and radiopharmaceutical compositions comprising the imaging agents, together with kits ... 06/01/06 - 20060115427 - Diagnosis and assessment of skeletal related disease using calcium 41 A method of determining calcium metabolism in a patient comprises the steps of administering radioactive calcium isotope 41Ca to the patient, allowing a period of time to elapse sufficient for dissemination and reaction of the radioactive calcium isotope 41Ca by the patient, obtaining a sample of the radioactive calcium isotope ... 06/01/06 - 20060115426 - Methods of detecting breast cancer, brain cancer, and pancreatic cancer The present invention discloses methods for detecting breast cancer, brain cancer, and pancreatic cancer via nuclear imaging using certain phospholipid ether analogs. ... 06/01/06 - 20060115425 - Substituted amides The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes ... 06/01/06 - 20060115424 - Combination therapy of oxaliplatin and radioactively doped particles treating cancer A method of treating cancer in a patient comprising administering to the patient an amount of oxaliplatin in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have a synergistic anticancer effect. ... 05/25/06 - 20060110323 - Method of imaging cell death in vivo The present invention relates to a method and a kit for detecting cell death or another condition characterized by an increase in the extracellular level of phosphatidylserine in a mammalian subject. The method involves administering a radionuclide-labeled compound that comprises a C2 domain of a protein or an active variant ... 05/25/06 - 20060110322 - Assay for vitamin b12 absorption and method of making labeled vitamin b12 The invention provides methods for labeling vitamin B12 with 14C, 13C, tritium, and deuterium. When radioisotopes are used, the invention provides for methods of labeling B12 with high specific activity. The invention also provides labeled vitamin B12 compositions made in accordance with the invention. ... 05/18/06 - 20060104897 - Method for diagnosing and treating nis-expressing carcinomas and metastases The present invention relates to a method for diagnosing and/or treating sodium-iodide symporter (NIS)-expressing primary carcinomas and metastases, preferably glandular carcinomas, in particular carcinomas of the thyroid, of the salivary gland, of the uterus and carcinomas of the breast, and to a pharmacological composition comprising substances which induce and/or increase ... 05/04/06 - 20060093552 - Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluoresence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates ... 05/04/06 - 20060093551 - Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers The present invention relates to novel benzo[1,2,5]oxadiazoles and benzo[1,2,5]thiadiazoles of formula (I) wherein X is O or S, R1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-18F-ethylamino)-thiazol-2-yl or a group of formula (a) wherein Y is CH or N, R2 is NHCH3, NH11CH3, N(CH3)11CH3, N(CH3)2, N(11CH3)2, NH(CH2)nF, NH(CH2)n18F, N(CH3)(CH2)nF, N(CH3)—(CH2)n 18F, O—(CH2)nF, O—(CH2)n 18F, CONH(CH2)nF ... 04/20/06 - 20060083682 - Novel methods of cancer therapy targeted against a cancer stemline Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment. ... 04/20/06 - 20060083681 - Compounds for myocardial perfusion imaging The present disclosure is directed to compounds comprising imaging moieties and their use for diagnosing certain disorders. ... 04/20/06 - 20060083680 - Diphenyl ether derivatives and their use for imaging serotonin transporters This invention relates to diphenyl ether derivatives and their use in imaging of Serotonin Transporters (SERTS). The present invention also provides diagnostic compositions comprising the compounds of the present invention, and a pharmaceutically acceptable carrier or diluent. The invention further provides a method of imaging SERTS, comprising introducing into a ... 04/20/06 - 20060083679 - Agents with selective k-opioid receptor affinity Compounds and compositions that are salvinorin A and salvinorin B derivatives that demonstrate selectivity and/or potency for the k-opioid receptor (KOR), allowing for their use as medicines, as well as chemical probes (both radiolabeled and cold) for fields utilizing the techniques of radiolabeled binding assays. ... 04/20/06 - 20060083678 - Radio-labeled compounds, compositions, and methods of making the same 18F radio-labeled compounds, methods of making the radio-labeled compounds, and applications of the same are disclosed. ... 04/20/06 - 20060083677 - Solid-phase fluorination of benzothiazoles The invention provides a process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I) SOLID SUPPORT-LINKER-X-TRACER (I) wherein X is a group which promotes nucleophilic substitution at a specific site on the attached TRACER and the TRACER is of formula (A). ... 04/20/06 - 20060083676 - Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands In a preferable embodiment, X represents O; R1 represents C1-6alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen ... 04/13/06 - 20060078495 - Stereoisomers of fatty acid analogs for diagnostic imaging The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more ... 04/13/06 - 20060078494 - Use of inhibitors of 24-hydroxylase in the treatment of cancer The present invention relates to a method of treating cancer in a subject. The method comprises administering to a subject suffering from cancer a therapeutically effective amount of a 24-hydroxylase inhibitor in combination with a second amount of a suitable cancer therapeutic. The 24-hydroxylase inhibitor can be coadministered with a ... 04/13/06 - 20060078493 - Methods and apparatus for localized administration of inhibitory moieties to a patient Methods and devices are provided for the localized administration to a patient of moieties effective for inhibiting unwanted cellular growth, including restenosis of an artery treated with a stent implant for blockage of blood flow by an atherosclerotic lesion. After implantation of a medical device capable of moiety-binding, moieties effective ... 04/06/06 - 20060073095 - Methods for screening antibody-producing cells on heterogeneous antigen substrates Methods and compounds are disclosed that relate to screening and selection of monoclonal antibodies specific for antigens in heterogeneous antigen mixtures. Antibody-secreting cells such as hybridomas are modified to make them capable of directly binding antigens by capturing their secreted antibody products onto their surface membranes in appropriate binding density ... 03/30/06 - 20060067881 - Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products Stable isotope labeling and neutron activation to measure biological functions are provided, as are the use and method of adding a chemical monitor to correct for neutron flux to sample vials prior to the addition of sample is presented, and the use of stable isotopes as a chemical bar code ... 03/30/06 - 20060067880 - Labeled creatine ethyl ester hydrochloride The present invention relates to various radiolabeled creatine ethyl ester hydrochloride compounds. Any carbon, hydrogen or nitrogen atom of the compounds may be radiolabeled using 14C, 13C, 2H, 3H or 15N atoms. ... 03/30/06 - 20060067879 - Diagnosis of diseases associated with cox-2 expression Derivatives of cyclooxygenase-2 inhibitor compounds are made incorporating a label that can be identified upon administration into the body of a mammal and subsequent binding of the compounds with cyclooxygenase-2 that is overexpressed due to a disease condition such as cancer. ... 03/23/06 - 20060062725 - Methods for preparing metal-carborane complexes for radioimaging and radiotherapy wherein M is selected from a radioisotope of rhenium (Re), technetium (Tc) and any other radioisotope binding in the same fashion, X is the same of different and is, independently, any suitable ligand and m is the formal charge for ligand X, with a nido-carborane or a closo-carborane in the ... 03/09/06 - 20060051291 - Synthesis of radiolabeled sugar metal complexes The invention provides a method for manufacturing or preparing neutral, low molecular weight 99mTc-labeled and 186Re-labeled carbohydrate complexes with an improved radiochemical yield from a simple functionalized sugar, such as glucosamine. In particular the synthesis relies on single ligand transfer (SLT) or double ligand transfer (DLT) reactions for converting a ... 03/09/06 - 20060051290 - Short carbon nanotubes as adsorption and retention agents A method for delivering a radiotherapeutic agent to a target, comprises administering a composition comprising water-soluble nanotubes having an average length less than 50 nm and a radionuclide so as to expose the target to the composition. The nanotubes can be functionalized with a monoclonal antibody having an affinity for ... 03/02/06 - 20060045845 - Neux- a new composition of matter This patent application is for a new composition of matter called “neuX”. It consists of two or more fundamental particles, called neutrons, that have no electric charge and are bound together by the so-called “strong forces”. Units of neuX, which may consist of any number of neutrons, are for use ... 02/23/06 - 20060039856 - Magnetic resonance with stimulation This invention involves blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) using external stimuli. Different colors of light can be used as the stimulus to assess differential BOLD response to diagnose neurological disorders (e.g., Parkinson's disease, attention deficit disorder, schizophrenia, and substance abuse). In addition, very low dose ... 02/23/06 - 20060039855 - Solid phase preparation of 18f-labelled amino acids A process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LIKER-SO2—O-TRACER (I) with 18F— to produce the labelled tracer of formula (II). ... 02/16/06 - 20060034758 - Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of ... 02/02/06 - 20060024229 - Method and product for locating an internal bleeding site A method is provided for localizing an internal bleeding site whereby a protein or other factor involved in the clotting process is complexed to an imaging agent and injected into a patient believed to be at risk of internal bleeding. A clot in the patient will naturally accumulate a certain ... 01/26/06 - 20060018827 - Positron therapy of inflammation, infection and disease This invention provides methods for positron therapy of inflammation, infection and disease which comprise administering to a subject a positron emitter or an agent labeled with a positron emitter, wherein the positron emitter or agent binds to or is taken up by affected tissue or by cells at the site ... 01/26/06 - 20060018826 - Biologic modulations with nanoparticles Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a ... 01/26/06 - 20060018825 - Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change The present invention provides compounds having high affinity for amyloid β-protein which are for the diagnosis of diseases in which amyloid β-protein accumulates, for agents for specifically staining amyloid β-protein, and for the treatment and/or prophylaxis of diseases in which amyloid β-protein accumulates. The present invention also provides probes and ... 01/05/06 - 20060002853 - Stilbene derivatives and their use for binding and imaging amyloid plaques This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method ... 01/05/06 - 20060002852 - Targeted and high density drug loaded polymeric materials Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and ... 01/05/06 - 20060002851 - Methods for carbon isotope labeling synthesis by transition metal-promoted carbonylation via isocyanate using azides and carbon-isotope monoxide Methods and reagents for transition metal-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided. ... 01/05/06 - 20060002850 - Radiolabeled lymphatic staining agents and methods for making A radiolabeled lymphatic staining agent is mixed on site with a much larger amount, on a weight basis, of a non-radiolabeled lymphatic staining agent to form an injectable radiolabeled lymphatic staining agent suitable for surgical use in humans. Preferably, the radiolabel is I-125, because it has a 60-day half-life which ... 12/29/05 - 20050287065 - Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject System for analyzing an in vivo response of a subject include a radiation detector for detecting radiation present in at least one localized solid tissue region of interest in a subject associated with internal activity of an administered quantity of an analyte comprising at least one of C-14 labeled glucose, ... 12/22/05 - 20050281738 - Method and means for detecting inflammatory processes A method of detecting inflammatory processes comprises (a) administering per-orally or per-rectally a composition comprising a diagnostically effective amount of L-[guanido-15N2]-arginine, L-[guanido-15N]-arginine, their mixtures and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; (b) collecting a sample of exhaled air, saliva or urine; (c) determining 15NO in the air ... 12/22/05 - 20050281737 - Stablilized and lyophilized radiopharmaceutical agents A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal ... 12/15/05 - 20050276755 - Formulation of tc and re carbonyl complexes using stannous ion as the reductant for pertechnetate and perrhenate wherein M is as defined above, Lx is a monodentate or multidentate ligand or a mixture of these ligands, and n is a charge of the ligand Lx increased with one+charge. The invention also is directed to novel compounds, and kits for carrying out the disclosed methods. ... 12/15/05 - 20050276754 - Bridged aromatic substituted amine ligands with donor atoms The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these ... 12/15/05 - 20050276753 - Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal ... 12/15/05 - 20050276752 - Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal ... 12/15/05 - 20050276751 - System and method for an automated synthesis of gallium-68 generator-based radiopharmaceutical agents Systems and methods are described for efficiently producing a radiopharmaceutical agent. The system includes a generator that provides an admixture comprising hydrochloric acid and gallium-68 (Ga-68). A heater initiates a removal process by evaporating the hydrochloric acid from the admixture resulting in a substantially purified Ga-68. A plurality of valves ... 12/15/05 - 20050276750 - Agents for imaging and diagnostic methods using them The present invention provides novel compounds that bind selectively to cells undergoing perturbations and alterations of the normal organization of their plasma membrane, while binding to a lesser degree to cells having membranes of normal organization, and their uses as diagnostic probes. Said compounds and methods used therein may be ... 12/08/05 - 20050271586 - Design and synthesis of renal dipeptidase inhibitors Aminophosphinic acid derivatives were synthesized as potential inhibitors of renal dipeptidase, an enzyme overexpressed in benign and malignant colon tumors. Several compounds showed potent enzyme-inhibitory activity. These compounds can be used therapeutically and diagnostically for treatment and detection of tumors. ... 12/08/05 - 20050271585 - Extended conjugated polymers A polymer is conjugated to a plurality of molecules having at least a functionality and further comprises an active agent, such as a diagnostic agent or a therapeutic agent. The diagnostic agent is capable of generating a signal detectable by a medical imaging technique. The conjugated polymer has an extended ... 12/08/05 - 20050271584 - Biphenyls and fluorenes as imaging agents in alzheimer's disease This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method ... 12/01/05 - 20050265923 - Embolus therapy using insoluble microparticles or vesicles containing contrast agents The invention provides a method of embolus therapy comprising administering into the vasculature of a perfused zone of tissue in a human or non-human animal subject a composition comprising particles of a size or formulation selected to generate emboli at a target site within said subject, characterised in that as ... 12/01/05 - 20050265922 - Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof Briefly described, embodiments of this disclosure include multimodality nanostructures, methods of forming the multimodality nanostructures, and methods of using the multimodality nanostructures. ... 12/01/05 - 20050265921 - Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or ... 11/24/05 - 20050260130 - Catalytic radiofluorination One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine ... 11/24/05 - 20050260129 - Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams A bio-molecular contrast agent (BMCA) is introduced into a biological organism such that the agent binds or reacts with target tissue within that organism. The BMCA is also signal-giving, and signal reactive, capable of being inactivated by delivery of energy thereto. By monitoring the decrease in signal strength of the ... 11/24/05 - 20050260128 - Carboranylporphyrins and uses thereof The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing 5, 10, 15, 20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy ... 11/24/05 - 20050260127 - Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic namely Biphenyl; arylpiperidine; Arylpiperazine; 1,4 dyhydropyridine Dihydropyrimidone; 1,4 benzodiazepine-2-one; 1,5 benzodiazepine-2-one; 1,4-benzodiazepine-2,5 diones; pyrrolo2,1-c 1,4 benzodiazepines 5,11 diones; 1,4 benzothiazepine-5-ones; 5,11-dihydro-benzo pyrido 3,2b 1,4 diazepine-6-ones; Benzopyrane; Chromone; Benzopyranone; Coumarine, pyranocoumarine; Benzopiperazinones; Quinazolinone; Quinazolindione; Quinoxalinone; Imidazoquinoxaline; indole; Benzimidazole Benzofurane Benzothiophene; SIGNAL is a signal entity for medical imaging diagnostic, and pharmaceutically ... 11/24/05 - 20050260126 - Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein or a salt or solvate thereof. ... 11/24/05 - 20050260125 - Imaging compounds The invention relates to compounds of formula: (I) or a salt or solvate thereof, wherein: R1 is —11CH2R5 or [18F]—C1-4 fluoroalkyl wherein R5 is hydrogen or C1-4 alkyl; R2 is hydrogen or C1-4 alkyl; R3 is halo; and R4 is halo, C1-4 alkylthio, or C1-4 alkyl; and their use for ... 11/24/05 - 20050260124 - Method of diagnosing risk of myocardial infarction It is intended to provide a means of diagnosing myocardial infarction which shows a high accuracy and a high predictability. The risk of myocardial infarction is diagnosed by a method comprising the following steps: (i) the step of analyzing 2 or more polymorphisms among 10 gene polymorphisms or 5 gene ... 11/17/05 - 20050255040 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is ... 11/17/05 - 20050255039 - Gel injection treatment of breast, fibroids & endometrial ablation A method and apparatus for treatment of diseases of a breast, fallopian tube and female reproductive organs by injecting/delivering a treatment substance/chemo-gel, directly into the target tissue of the body organ, and thereby leaving the remaining body organs relatively unaffected. Specific formulations and composition of treatment substances are provided. The ... 11/17/05 - 20050255038 - Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof Disclosed are conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof, e.g. for imaging cancer cells and tumors in vivo. ... 11/10/05 - 20050249663 - Coadministration of transport protein with conjugated cobalamin to deliver agents Cobalamin transport proteins are administered in combination with cobalamin coupled to a diagnostic or pharmaceutically active agents to increase the extent of absorption of the diagnostic or pharmaceutically active agent. Cobalamin transport proteins include, but are not limited to intrinsic factor, transcobalamin I, transcobalamin II and transcobalamin III. The combination ... 11/10/05 - 20050249662 - Marked maleimide compounds, method for preparing same and use thereof for marking macromolecules Process for preparing these compounds; their use for labelling macromolecules, and complexes of these compounds with a macromolecule. Detection and analysis kit, or diagnosis kit, comprising the said complexes. Use of the complexes in a medical imaging process such as positron emission tomography (PET). ... 11/03/05 - 20050244332 - Contrast agents for myocardial perfusion imaging The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging. ... 11/03/05 - 20050244331 - Labeled adenosine for use in positron emission tomography Radiolabeled adenosine or radiolabeled adenosine containing molecules for use in positron emission tomography for assessing alterations in adenylate metabolism in a patient are provided. ... 10/27/05 - 20050238577 - Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling The methods of the present invention allow for the non-invasive or minimally invasive isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling. Once isolated, the labeled epithelial cells or their labeled biochemical contents find use as kinetic biomarkers of diseases of epithelial tissues including ... 10/27/05 - 20050238576 - Delivery methods, systems and components for use with radiopharmaceutical substances A method and apparatus of dispensing a radiopharmaceutical wherein a source of flushing fluid is connected to a first port of a fluid delivery set; a pressurizing unit of a powered injector system (including a powered injector and the pressurizing unit) is connected to a second port of the fluid ... 10/20/05 - 20050232861 - Microfluidic apparatus and method for synthesis of molecular imaging probes including fdg The invention provides a method and apparatus for preparation of radiochemicals wherein the reaction that couples the radioactive isotope to the reactive precursor to form a positron-emitting molecular imaging probe is performed in a microfluidic environment. The method comprises: providing a micro reactor; introducing a liquid reactive precursor dissolved in ... 10/20/05 - 20050232860 - Use of edg-receptor agonists for the treatment of hypertension Treatment and/or prophylaxis of hypertension involving administering a therapeutically active amount of an edg-receptor agonist or a pharmaceutically acceptable salt thereof. Preferably the edg-receptor agonist is a highly selective I1-receptor agonist and essentially devoid of α2-receptor agonist activity and has an imidazoline structure. Hence, hypertension may be treated without causing ... 10/13/05 - 20050226811 - Radioactive iodine-labeled compound wherein X represents a radioactive iodine atom which may substitute at an arbitrary position on the benzene ring (preferably 123I, 125I and the like.), n represents an integer of 1 to 3, R1 and R2 each independently represent a substituted or unsubstituted alkyl group, Y represents an alkylene group having ... 10/13/05 - 20050226810 - Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis Substituted porphyrin and azaporphyrin deviations with various substitutents in the 12- and 17-positions of the prophyrin skeleton as pharmaceutical agents for use in photodynamic therapy, MRI diagnosis, and radiodiagnostics. ... 09/29/05 - 20050214204 - Radiolabeled neurokinin-1 receptor antagonists The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals. ... 09/22/05 - 20050207973 - Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy chromans Radiopharmaceutical compositions which are stabilized by addition of a hydrophilic 6-hydroxy-chroman derivative. ... 09/22/05 - 20050207972 - Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be ... 09/15/05 - 20050201930 - Contrast agents where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body, with the provisos that where V is angiotensin or a peptidic ... 09/08/05 - 20050196339 - Phospholipid analogs as diapeutic* agents and methods thereof The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers. ... 09/01/05 - 20050191238 - Contrast agents for myocardial perfusion imaging The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging. ... 08/25/05 - 20050186135 - Compositions, methods, apparatuses, and systems for singlet oxygen delivery Methods of treating tumors, lesions, and cancers comprising delivering to the affected site a combination of peroxide and hypochlorite anion. Hydrogen peroxide and sodium hypochlorite are possible sources of peroxide and hypochlorite anion, respectively. The reactants may be injected simultaneously or sequentially, and combine at the site to produce singlet ... 08/25/05 - 20050186134 - Method for preparing technetium-labeled antimony sulfide nanocolloid The present invention relates to a preparation method for technetium-antimony sulfide nanocolloid, more precisely, a preparation method for technetium-antimony sulfide nanocolloid which is characterized by the processes of mixing and stirring of pertechnetate and antimony sulfide nanocolloid in the presence of borohydride exchange resin and obtaining technetium-antimony sulfide nanocolloid radioactive ... 08/18/05 - 20050180918 - Stabilization of radiopharmaceutical compositions using hydrophilic thioethers Radiopharmaceutical compositions which are stabilized by addition of a hydrophilic thioether. ... 08/18/05 - 20050180917 - Delivery of neutron capture elements for neutron capture therapy Neutron capture therapy (NCT) for example, Boron neutron capture therapy (BNCT) requires the delivery of a neutron capture element such as Boron to a target site to be treated, followed by irradiation with neutrons. The invention provides new means for delivery of the neutron capture element in the form of ... 08/11/05 - 20050175535 - Myocardial perfusion imaging method The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging. ... 08/11/05 - 20050175534 - Method of synthesizing compounds having a phosphorus-fluorine-18 bond Provided are methods for synthesizing radiotracers, including no carrier added (n.c.a.) tracers suitable as PET scan tracers that contain a 18F—P bond. The radiolabeled products may be synthesized from precursors including phosphorus(V) and/or phosphorus (III) atoms bound to a suitable leaving group or group(s). For example, precursors incorporating a nitrophenoxy ... 08/04/05 - 20050169837 - Coumarines useful as biomarkers The invention provides compounds of formula (I), wherein R, R1, R2, R3 and R4 are as defined in the description, and their preparation. The compounds of formula I are useful as biomarkers. ... 07/21/05 - 20050158240 - Method for labeling with tritium The present invention provides a tritium-labeling method which allows the introduction of tritium at the last stage of preparation and thus the preparation of the tritium-labeled compound having a high specific radioactivity, and said compound prepared by the method. ... 07/21/05 - 20050158239 - Perturbed membrane-binding compounds and methods of using the same The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes. ... 07/14/05 - 20050152835 - Technetium-99m glucarate methods of use for monitoring tissues A method of characterizing a resistant tissue includes imaging 99mTc-GLA localized in one or more resistant cells and providing additional treatment to the resistant cells based on the image of the 99mTc-GLA localized in the cells. The method may be used to detect and develop treatments for cells and tissue ... 06/23/05 - 20050136003 - Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use The present invention is directed to novel chemical agents for compounds and their use for imaging myocardial perfusion. The invention also is directed to a kit for forming such novel agents. The chemical agents for the present invention comprising (a) a cardiotonic moiety and (b) an imaging moiety. ... 06/23/05 - 20050136002 - Use of particulate contrast agents in diagnostic imaging for studying physiological paramaters The present invention relates to a method of imaging of an animate human or non-human animal body, which method comprises: administering parenterally to said body a particulate material comprising a matrix or membrane material and at least one contrast generating species, which matrix or membrane material is responsive to a ... 06/23/05 - 20050136001 - Fluorinated carbohydrate conjugates Disclosed are novel conjugates that include fluorinated carbohydrate molecules and methods for synthesizing the conjugates. The fluorinated carbohydrate molecule may include a radioisotope. The method of synthesizing the conjugate is useful for labeling selected molecules, and the conjugates may be useful in diagnostic or therapeutic methods. Particularly, the conjugates may ... 06/16/05 - 20050129612 - Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging This invention relates to a method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Furthermore, radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the ... 06/16/05 - 20050129611 - Drugs for the diagnosis of tissue reproductive activity or the treatment of proliferative diseases The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease. ... 06/16/05 - 20050129610 - Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the a7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of ... 06/09/05 - 20050123475 - Preparation and use of alkylating agents The present disclosure provides methods of synthesizing alkylating agents and methods of use. ... 06/09/05 - 20050123474 - Methods and apparatus for continuous large-scale radiolabeling of proteins Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies. ... 06/09/05 - 20050123473 - Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same Substituted 1,4,7-triazacyclononane-N,N,′N″-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder. ... 06/02/05 - 20050118098 - Radioactive ion The present invention relates to a method for implantation of Xe isotopes in a matrix for production of 125I sources that do not shed radioactive atoms. 125Xe implanted at 12 kV in steel, titanium and gold does not evolve after more than 10 half-lives (380 h) and 125I from the ... ### FreshPatents.com Support |